Early aggressive treatment strategy against myasthenia gravis

European Neurology

Volumn 65, Issue 1, 2011, Pages 16-22

  Nagane, Yuriko ^a   Suzuki, Shigeaki ^b   Suzuki, Norihiro ^b   Utsugisawa, Kimiaki ^a  

^a Hanamaki General Hospital   (Japan)

^b KEIO UNIVERSITY   (Japan)

Author keywords

Aggressive therapy; Corticosteroids; High dose intravenous methylprednisolone; Myasthenia gravis; Plasmapheresis; Prednisolone

Indexed keywords

CALCINEURIN INHIBITOR; CHOLINESTERASE INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; PREDNISOLONE; TACROLIMUS;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG MEGADOSE; EARLY AGGRESSIVE THERAPY; EARLY INTERVENTION; FACE EDEMA; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MYASTHENIA GRAVIS; PLASMAPHERESIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THYMECTOMY; THYMOMA; TREATMENT DURATION; TREATMENT OUTCOME;

DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHYLPREDNISOLONE; MYASTHENIA GRAVIS; PLASMAPHERESIS; PREDNISOLONE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 78649370097     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000322497     Document Type: Article

References (24)

1. Patrick J, Lindstrom J: Autoimmune response to acetylcholine receptor. Science 1973; 180: 871-872.
2. Meriggioli MN, Sanders DB: Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 2009; 8:475-490.
3. Gilhus NE: Autoimmune myasthenia gravis. Exper t Rev Neurother 2009; 9: 351-358.
4. Keesey JC: Clinical evaluation and management of myasthenia gravis. Muscle Nerve 2004; 29:484-505.
5. Pascuzzi RM, Coslett HB, Johns TR: Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol 1984; 15:291-298.
6. Muscle Study Group: A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 2008; 71: 394-399.
7. Sanders DB, Evoli A: Immunosuppressive therapies in myasthenia gravis. Autoimmunity 2010; 43:428-435.
8. Grob D, Brunner N, Namba T, Pagala M: Lifetime course of myasthenia gravis. Muscle Nerve 2008; 37: 141-149.
9. Truhan AP, Ahmed AR: Corticosteroids: a review with emphasis on complications of prolonged systemic therapy. Ann Allergy 1989; 62: 375-391.
10. Brown ES, Suppes T: Mood symptoms during corticosteroid therapy: a review. Harvard Rev Psychiatry 1998; 5: 239-246.
11. Aarli JA: Myasthenia gravis in the elderly: is it different? Ann NY Acad Sci 2008; 1132: 238-243.
12. Evoli A, Batocchi AP, Minisci C, Di Schino C, Tonali P: Clinical characteristics and prognosis of myasthenia gravis in older people. J Am Geriatr 2000; 48:1442-1448.
13. Vincent A, Clover L, Buckley C, Grimley EJ, Rothwell PM: Evidence of underdiagnosis of myasthenia gravis in older people. J Neurol Neurosurg Psychiatry 2003; 74: 1105-1108.
14. Somnier FE: Increasing incidence of late-onset anti-AChR antibody-seropositive myasthenia gravis. Neurology 2005; 65:928-930.
15. Munakata R, Utsugisawa K, Nagane Y, Yamagata M, Oikawa M, Obara D, Tohgi H: The effect of combined therapy with immunoadsorption and high-dose intravenous methylprednisolone on myasthenia gravis. Eur Neurol 2002; 48:115-117.
16. Nagane Y, Utsugisawa K, Obara D, Kondoh R, Terayama Y: Efficacy of low-dose FK506 in the treatment of myasthenia gravis - a randomized pilot study. Eur Neurol 2005; 53: 146-150.
17. Newsom-Davis J, Wilson SG, Vincent A, Ward CD: Long-term effects of repeated plasma exchange in myasthenia gravis. Lancet 1979; 1:464-468. (Pubitemid 9127238)
18. Jaretzki A 3rd, Barohn RJ, Ernstoff RM, et al: Myasthenia gravis: recommendation for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000; 55:16-23.
19. Sato T, Anno M, Arai K, Yamawaki N, Kuroda T, Inagaki K: In vitro removal of anti-acetylcholine receptor antibodies with a new immunoadsorbent in sera from myasthenia gravis patients; in Atsumi K, Maekawa M, Ota K (eds): Progress in Artificial Organs. Cleveland, ISAO Press, 1983, pp. 719-722.
20. Shibuya N, Sato T, Osame M, Takegami T, Doi S, Kawanami S: Immunoadsorption therapy for myasthenia gravis. J Neurol Neurosurg Psychiatry 1994; 57: 578-581.
21. Tindall RSA, Rollins JA, Phillips JT, Greenlee RG, Wells L, Belendiuk G: Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 1987; 316:719-724.
22. Nagane Y, Suzuki S, Suzuki N, Utsugisawa K: Factors a ssociated with response to calcineurin inhibitors in myasthenia gravis. Muscle Nerve 2010; 41:212-218.
23. Slesak G, Melms A, Gerneth F, Sommer N, Weissert R, Dichgans J: Lateonset myasthenia gravis. Follow-up of 113 patients diagnosed after age 60. Ann NY Acad Sci 1998; 841:777-780.
24. Zinman L, Ng E, Bril V: IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology 2007; 68: 837-841.